If you are wondering whether Travere Therapeutics at around US$38.78 is offering value or asking too much, this breakdown is designed to help you make sense of the current price. The stock has been ...

Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, ...

Italian drive to increase diagnosis rates in children with severe genetic disorders is achieving transformative results. The ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 Stocks With Monster Returns. Travere Therapeutics grew its share ...

Notably, investors poured funds into industries with promising growth prospects, namely semiconductor and quantum computing, ...

The trial compares sparsentan, an oral pill developed by Travere Therapeutics, Inc., with the standard angiotensin receptor blocker irbesartan. Both drugs aim to slow kidney damage in focal segmental ...

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...

Full FDA approval covers proteinuria reduction in FSGS without nephrotic syndrome, a defined clinical subset differentiated ...

Regeneron and Telix announced a strategic radiopharma collaboration worth up to $4.3 billion. Daiichi Sankyo entered a $1.55 ...

The latest health news includes calls for transparency in FDA's accelerated drug approvals, expanded use of Travere's kidney drug, Roche's new study for gene therapy, and Hetero's global drug rollout ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.